Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Suicidal Ideation in the ED
NCT03502551Phase 2Withdrawn
- Sponsor
- University of California, Davis
- Start
- Apr 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in suicidal ideation, sponsored by University of California, Davis. Primary endpoints: Suicidal ideation at 24 hours post-infusion, Incidence of Discharge to Outpatient vs. Inpatient Facilities at 53 hours and 1 more. Planned start Apr 2019; status: withdrawn.
02
Drugs
ketamine
03
Conditions
suicidal ideation
Beyond the preview
Go deeper on NCT03502551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502551.